Cannabis drug interactions are the most clinically significant risk in medical cannabis use, and the one most often left out of the conversation entirely.
The mechanism is well understood. The specifics vary by drug, dose and individual, which is why this is a conversation with a clinician rather than something to resolve from an article.
This is not medical advice and it is not a complete list. TruMo Analytics is a cannabis testing laboratory. Do not start, stop or change any medication based on this page. Talk to your prescriber or pharmacist — a pharmacist is the most accessible interaction expertise available and is usually free to consult.
The Mechanism
Most drugs are metabolised by a family of liver enzymes called cytochrome P450, principally CYP3A4 and CYP2C9. These enzymes convert drugs into forms the body can eliminate.
Cannabinoids interact with this system. CBD in particular inhibits several of these enzymes, and THC interacts with them as well.
When an enzyme is inhibited, drugs it processes are cleared more slowly, so blood levels rise — potentially into a range that causes side effects or toxicity. Conversely, anything that induces those enzymes clears drugs faster, so levels fall and the drug may stop working.
This is the same mechanism behind the grapefruit warning on many prescriptions. Grapefruit inhibits CYP3A4, which is why it appears on so many medication labels. Cannabinoids act on the same system, more broadly.
Where the Risk Is Highest
Interactions matter most for drugs with a narrow therapeutic index — where the gap between an effective dose and a harmful one is small. For those drugs, a modest change in blood level is clinically significant.
Anticoagulants
Warfarin is the clearest documented example. Case reports describe elevated INR — a measure of how long blood takes to clot — in patients using cannabis alongside warfarin, indicating increased anticoagulation and bleeding risk.
Anyone on warfarin who uses cannabis should be having their INR monitored, and their prescriber needs to know.
Anticonvulsants
Clinically important, and complicated by the fact that some patients use cannabis specifically for seizure control.
Interactions between CBD and clobazam are well documented — CBD raises levels of clobazam’s active metabolite, which can increase sedation. Interactions with valproate have been associated with elevated liver enzymes. Other anticonvulsants have their own considerations.
This is a case where monitoring and dose adjustment by a prescriber is the answer, not avoidance or self-management.
Sedatives and CNS depressants
Benzodiazepines, opioids, sleep medications, alcohol. The interaction here is additive rather than metabolic — combined sedation, impaired coordination and, with some combinations, respiratory considerations.
The metabolic interaction may also raise levels of some of these drugs, compounding the effect.
Psychiatric medications
Antidepressants, antipsychotics and mood stabilisers are processed by the same enzyme systems. Beyond levels, there is the pharmacodynamic question — cannabis affects mood, anxiety and, in susceptible individuals, psychosis risk, which interacts with what these medications are treating. See cannabis and mental health.
Cardiovascular medications
THC raises heart rate and can affect blood pressure, which is relevant alongside antihypertensives and antiarrhythmics. Some statins are metabolised by affected enzymes.
Immunosuppressants
Tacrolimus and similar drugs have narrow therapeutic ranges and are processed by CYP3A4. For transplant patients this is a serious consideration — and transplant patients are also among those most at risk from fungal contamination in untested product. See the risks of untested cannabis products.
Chemotherapy
Many chemotherapy agents are metabolised by the same enzymes, and cannabis is frequently used for treatment-related nausea. That combination needs oncologist oversight rather than independent management.
Route Changes the Picture
How cannabis is taken affects the interaction profile.
Ingested cannabis passes through the liver before reaching general circulation, which means maximum exposure of the enzyme systems. Edibles, capsules and tinctures carry the highest interaction potential.
Inhaled cannabis enters the bloodstream through the lungs, bypassing first-pass metabolism. Interaction potential is lower, though not absent.
Topicals act locally and do not meaningfully enter systemic circulation, so interaction risk is minimal for conventional topicals. Transdermal patches are engineered to deliver systemically and are a different case.
See forms of medical cannabis.
Why Dose Consistency Matters Here
An interaction depends on how much cannabinoid is present. That makes accurate, consistent dosing part of managing interaction risk rather than a separate concern.
If a product’s actual content varies substantially from its label — or between units in the same package — the cannabinoid exposure varies with it, and so does the effect on drug metabolism. For a patient on a narrow-therapeutic-index medication, that variability is a real clinical problem.
This is one of the more direct connections between laboratory testing and patient safety. Verified potency and, for infused products, verified homogeneity are what make a dose reproducible. See why edibles are tested differently.
What to Actually Do
- Tell every prescriber. Cannabis is a substance that affects drug metabolism. It belongs on your medication list.
- Talk to a pharmacist. They have interaction databases, they are accessible without an appointment, and this is exactly what they are for.
- Do not stop prescribed medication on your own. Withdrawal from some medications is dangerous independently of losing the therapeutic effect.
- Start low and change one thing at a time. If you are adding cannabis to an existing regimen, small doses and slow increases give you and your clinician a chance to see what happens. See dosage basics.
- Watch for signals. Unusual sedation, dizziness, confusion, bruising or bleeding, or a previously stable condition changing.
- Keep monitoring current. If you take a medication with routine blood monitoring, keep it up and mention the cannabis.
- Use consistent, verified products. Reproducible exposure is part of managing this.
Being Honest About What Is Unknown
The research base on cannabis drug interactions is thinner than it should be. Much of what is known comes from case reports, pharmacokinetic studies and the CBD epilepsy trials, rather than from systematic study across drug classes.
That means absence of a documented interaction is not evidence of safety — it frequently means nobody has looked. Which is an argument for more caution rather than less, and for keeping the people managing your medications informed.
See working with a qualified cannabis clinician and medical cannabis for older adults, where multiple medications make this most relevant.